Literature DB >> 15269306

Fluorescence in situ hybridization identifies cryptic t(16;16)(p13;q22) masked by del(16)(q22) in a case of AML-M4 Eo.

Shakil H Merchant1, Skip Haines, Bryan Hall, John Hozier, David S Viswanatha.   

Abstract

We report a patient presenting with acute myeloid leukemia (AML)-M4 Eo, in whom conventional cytogenetic analysis revealed a 46, XY, del(16)(q22) karyotype. Molecular analysis of the bone marrow cells using reverse transcriptase polymerase chain reaction (RT-PCR) identified a CBFbeta-MYH11, "type A" fusion transcript. However, despite a thorough reevaluation, a balanced chromosome 16 abnormality could not be definitively identified by cytogenetics. Since there exists a small possibility of obtaining a false-positive PCR result, fluorescence in situ hybridization (FISH) analysis using dual-color, break-apart probes for CBFbeta was performed to elucidate the mechanism of fusion gene formation and thus confirm the RT-PCR results. FISH analysis clearly revealed a cryptic t(16;16), which was probably masked by the del(16)(q22). FISH is the preferred diagnostic procedure to elucidate the CBFbeta-MYH11 fusion in this situation, and resolves the possibility of both false-positive and false-negative results with RT-PCR technique. Due to the improved prognosis of AML associated with the CBFbeta-MYH11 fusion compared to AML generally, we recommend the use of FISH for detection of inv(16)/t(16;16)/CBFbeta-MYH11 in patients with failed, complex, or apparently normal cytogenetics, and in whom the cell morphology indicates the strong possibility of this gene fusion.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15269306      PMCID: PMC1867642          DOI: 10.1016/S1525-1578(10)60521-1

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  16 in total

1.  Identification of false-positive CBFbeta/MYH11 RT-PCR results.

Authors:  S M Hackwell; D O Robinson; J F Harvey; F M Ross
Journal:  Leukemia       Date:  1999-10       Impact factor: 11.528

2.  Cytogenetically cryptic AML1-ETO and CBF beta-MYH11 gene rearrangements: incidence in 412 cases of acute myeloid leukaemia.

Authors:  D Rowe; S J Cotterill; F M Ross; D J Bunyan; S J Vickers; J Bryon; D J McMullan; M J Griffiths; J T Reilly; E A Vandenberghe; G Wilson; A E Watmore; N P Bown
Journal:  Br J Haematol       Date:  2000-12       Impact factor: 6.998

Review 3.  Prognostic factors for selecting curative therapy for adult acute myeloid leukemia.

Authors:  C D Bloomfield
Journal:  Leukemia       Date:  1992-11       Impact factor: 11.528

4.  High concordance of karyotype analysis and RT-PCR for CBF beta/MYH11 in unselected patients with acute myeloid leukemia. A single center study.

Authors:  M Mitterbauer; K Laczika; M Novak; G Mitterbauer; B Hilgarth; H Pirc-Danoewinata; I Schwarzinger; O A Haas; C Fonatsch; K Lechner; U Jaeger
Journal:  Am J Clin Pathol       Date:  2000-03       Impact factor: 2.493

5.  Detection of inv(16) and t(16;16) by fluorescence in situ hybridization in acute myeloid leukemia M4Eo.

Authors:  J M Hernández; M B González; I Granada; N Gutiérrez; C Chillón; F Ramos; J M Ribera; M González; E Feliu; J San Miguel
Journal:  Haematologica       Date:  2000-05       Impact factor: 9.941

Review 6.  Molecular pathogenesis of the chromosome 16 inversion in the M4Eo subtype of acute myeloid leukemia.

Authors:  P P Liu; A Hajra; C Wijmenga; F S Collins
Journal:  Blood       Date:  1995-05-01       Impact factor: 22.113

7.  CBFB/MYH11 fusion in a patient with AML-M4Eo and cytogenetically normal chromosomes 16.

Authors:  H Pirc-Danoewinata; H G Dauwerse; M König; I Chudoba; M Mitterbauer; U Jäger; M H Breuning; O A Haas
Journal:  Genes Chromosomes Cancer       Date:  2000-10       Impact factor: 5.006

8.  Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study.

Authors:  K Mrózek; T W Prior; C Edwards; G Marcucci; A J Carroll; P J Snyder; P R Koduru; K S Theil; M J Pettenati; K J Archer; M A Caligiuri; J W Vardiman; J E Kolitz; R A Larson; C D Bloomfield
Journal:  J Clin Oncol       Date:  2001-05-01       Impact factor: 44.544

9.  Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. A unique cytogenetic-clinicopathological association.

Authors:  M M Le Beau; R A Larson; M A Bitter; J W Vardiman; H M Golomb; J D Rowley
Journal:  N Engl J Med       Date:  1983-09-15       Impact factor: 91.245

10.  Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside.

Authors:  H M Ghaddar; W Plunkett; H M Kantarjian; S Pierce; E J Freireich; M J Keating; E H Estey
Journal:  Leukemia       Date:  1994-08       Impact factor: 11.528

View more
  2 in total

1.  Diagnostic molecular pathology, part 2: proteomics and clinical applications of molecular diagnostics in hematopathology.

Authors:  Georges J Netto; Rana Saad
Journal:  Proc (Bayl Univ Med Cent)       Date:  2005-01

2.  Multiplexed automated digital quantification of fusion transcripts: comparative study with fluorescent in-situ hybridization (FISH) technique in acute leukemia patients.

Authors:  Ariz Akhter; Muhammad Kashif Mughal; Ghaleb Elyamany; Gary Sinclair; Raja Zahratul Azma; Noraidah Masir; Salwati Shuib; Fariborz Rashid-Kolvear; Meer-Taher Shabani-Rad; Douglas Allan Stewart; Adnan Mansoor
Journal:  Diagn Pathol       Date:  2016-09-15       Impact factor: 2.644

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.